Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.16 USD | -1.69% | -5.69% | +9.38% |
Apr. 01 | Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 05 | North American Morning Briefing : S&P 500 Futures -2- | DJ |
Business Summary
Number of employees: 1
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
T-cell Therapies
100.0
%
| 3 | 100.0 % | 0 | 100.0 % | -99.83% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 3 | 100.0 % | 0 | 100.0 % | -99.83% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Dale Hogue
CEO | Chief Executive Officer | 54 | Dec. 28 |
Director of Finance/CFO | 62 | 21-02-16 | |
Chief Tech/Sci/R&D Officer | 44 | 22-08-03 | |
Raffaele Baffa
CTO | Chief Tech/Sci/R&D Officer | 65 | 20-11-16 |
Adam Levy
IRC | Investor Relations Contact | - | 20-10-31 |
Corporate Officer/Principal | 39 | Feb. 21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jaime Vieser
BRD | Director/Board Member | 54 | 20-12-15 |
Holger Weis
CHM | Chairman | 61 | 20-12-15 |
Robert Postma
BRD | Director/Board Member | 70 | 21-02-04 |
Dale Hogue
CEO | Chief Executive Officer | 54 | Dec. 28 |
Director/Board Member | 56 | 23-03-29 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 16,012,479 | 15,308,964 ( 95.61 %) | 0 | 95.61 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.38% | 18.89M | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- TCRT Stock
- Company Alaunos Therapeutics, Inc.